Published in TB and Outbreaks Week, September 3rd, 2002
The company reported second quarter 2002 revenues of $2.4 million compared with second quarter 2001 revenues of $1.8 million. Results for the second quarter of 2002 include a $1.0 million payment from Merial for the exercise of additional options under a 1995 agreement for veterinary preventive infectious disease vaccines, and a license payment from Centocor.
The net loss for the second quarter of 2002 was $5.0 million or $0.25 per share, compared with a net loss...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week